Phentermine Juno ER tablets are a private prescription weight loss medication, the result of a joint Australian and Swiss development.
The resources provided on this website are for informational purposes only and should not be considered as a substitute for the advice of your healthcare professional. Any information provided on this website should be discussed with your healthcare professional.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Juno PC does not endorse the organisations or views represented by external sites and takes no responsibility for the material contained on this site.
Juno PC does not endorse the organisations or views represented by external sites and takes no responsibility for the material contained on this site.
Juno PC does not endorse the organisations or views represented by external sites and takes no responsibility for the material contained on this site.
This content is only available to Australian citizens who have been prescribed Phentermine Juno ER and their APHRA registered healthcare professionals.
You may access this content using the password supplied by Juno PC, if you are a healthcare professional, or provided by your healthcare professional, if you are a patient.
| PBS INFORMATION: This product is not listed on the PBS. |
Please review full Product Information before prescribing.
Product Information can be requested from 1800 620 076 or medical-enquiries@junopharm.com.au
Phentermine Juno ER Minimum PI: Phentermine Juno ER extended release tablet contains phentermine hydrochloride. Bioequivalence has been established with phentermine extended release ion exchange resin capsules on which the clinical data is based. Indications: management of obesity as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction in obese patients with a body mass index (BMI) of 30 kg/m2 or greater. Contraindications: Pulmonary artery hypertension; existing heart valve abnormalities or heart murmurs; moderate to severe arterial hypertension; cerebro-vascular disease; severe cardiac disease including arrhythmias, advanced arteriosclerosis; known hypersensitivity to sympathomimetic drugs; hyperthyroidism; agitated states or a history of psychiatric illnesses including anorexia nervosa and depression; glaucoma; history of drug/alcohol abuse or dependence; concomitant treatment with Monoamine Oxidase (MAO) Inhibitors or within 14 days following their administration. Precautions: coadministration of drug products for weight loss; mild hypertension; diabetes; rapid weight loss; established coronary artery disease; epilepsy. Interactions: selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, paroxetine), ergot-like drugs and clomipramine; fenfluramine/dexfenfluramine; psychotropic drugs, including sedatives; sympathomimetic agents; anti-hypertensive agents; adrenergic neurone blocking drugs such as clonidine, methyldopa and guanethidine; monoamine oxidase inhibitors; thyroid hormones; alcohol. Adverse effects: Cardiovascular: Valvular Heart Disease and Primary Pulmonary Hypertension; palpitations, tachycardia, elevation of blood pressure, precordial pain. stroke, angina, myocardial infarction, cardiac failure, cardiac arrest. Central Nervous System: Overstimulation, restlessness, nervousness, insomnia, tremor, dizziness and headache. euphoria followed by fatigue and depression, psychotic episodes and hallucinations. Gastrointestinal: Nausea, vomiting, dry mouth, abdominal cramps, unpleasant taste, diarrhoea, constipation. Other: Micturition disturbances, rash, impotence, changes in libido, facial oedema. Dosage and administration: Adults and adolescents over 12 years. One tablet daily at breakfast, swallowed whole. Evening dosing should be avoided, as this agent may induce insomnia. The recommended starting dose is 30mg daily. Larger framed individuals may require 40mg daily. The recommended maintenance dose, either continuous or intermittent is 15 to 40 mg daily depending on responsiveness. The recommended dose of phentermine should not be exceeded to increase the effect. Phentermine should not be combined with other appetite suppressants. Patients require medical review after a defined course of treatment, which should not exceed three months. Med308. Prepared May 2020.
Copyright © Juno PC Holdings Pty Ltd. 42 Kelso Street, Cremorne, VIC 3121, Australia. MED315. Issued August 2020.
